By Professor Michael Leonard Friedlander

Conference Papers

Goodwin P; Phillips K; West D; Ennis M; Hopper J; John EM; O'Malley F; Milne R; Andrulis I; Friedlander M; Longacre T, 2009, 'Prognosis in BRCA1, BRCA2 associated breast cancer (BC): a prospective Breast Cancer Family Registry (BCFR) international population-based cohort study.', in Cancer Research, American Association for Cancer Research (AACR), pp. 2072 - 2072, http://dx.doi.org/10.1158/0008-5472.sabcs-2072

Goodwin P; Phillips KA; West DJ; Ennis M; Hopper JL; John E; O Malley F; Milne RS; Andrulis I; Friedlander ML; Longacre T, 2009, 'Prognosis in BRCA1, BRCA2 associated breast cancer (BC): a prospective Breast Cancer Family Registry (BCFR) international population-based cohort study', in Cancer research, American Association Cancer Research, Philadelphia, PA, pp. 178S - 178S

Friedlander M; Hancock KC; Benigno B; Rischin D; Messing M; Stringer CA; Hodge JP; Ma B; Matthys G; Lager JJ, 2008, 'PAZOPANIB (GW786034) IS ACTIVE IN WOMEN WITH ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE AND PERITONEAL CANCERS: RESULTS OF A PHASE II STUDY', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SWEDEN, Stockholm, pp. 211 - 211, presented at 33rd European-Society-for-Medical-Oncology Congress, SWEDEN, Stockholm, 12 September 2008 - 16 September 2008, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259973300662&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Field KM; Phillips K; Jenkins MA; McKinley J; Weideman P; Price M; Friedlander M; McLachlan S; Lindeman G; Butow P, 2008, 'Complementary and alternative medicine (CAM) use in high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.1528

Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2008, 'Early detection of oxaliplatin-induced neurotoxicity: Getting it before it hurts', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.15015

Friedlander M, 2008, 'Medical Oncology Group of Australia (MOGA)/Novartis cancer achievement award', in Cancer Forum, pp. 27 - 31

Bennett BK; Goldstein D; Friedlander ML; Boyle F; De Souza PL; Wilken N; Hickie IB; Scott E; Lloyd AR, 2008, 'A prospective cohort study of fatigue after adjuvant therapy for breast cancer', in Psycho - Oncology, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. S36 - S37, presented at Psycho-Oncology 2008

Friedlander M; Hancock KC; Benigno B; Rischin D; Messing M; Stringer CA; Tay EH; Kathman S; Matthys G; Lager JJ, 2007, 'Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000455043701341&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Peate ML; Meiser B; Hickey MS; Thewes B; Butow PN; Saunders C; Rovelli S; Zorbas H; Friedlander ML, 2007, 'Breast cancer and fertility: Making hard choices easier - The development and evaluation of fertility-related decision aid for young women with early breast cancer', in Psycho - Oncology, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. S15 - S16, presented at Psycho-Oncology 2007

Dawson S; McKinley J; Jenkins M; McLachlan S; Lindeman G; Friedlander M; Hopper J; Phillips K, 2006, 'Cancer risk management practices of non-carriers within BRCA1/2 mutation positive families in the Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, GA, Atlanta, pp. 53S - 53S, presented at 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, GA, Atlanta, 02 June 2006 - 06 June 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000239009400210&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Thigpen T; Stuart G; du Bois A; Friedlander M; Fujiwara K; Guastalla JP; Kaye S; Kitchener H; Kristensen G; Mannel R; Meier W; Miller B; Poveda A; Provencher D; Stehman F; Vergote I, 2005, 'Clinical trials in ovarian carcinoma: Requirements for standard approaches and regimens', in Annals of Oncology, http://dx.doi.org/10.1093/annonc/mdi962

Mitchell P; Goldstein D; Michael M; Beale P; Friedlander M; Zalcberg J; Clarke S; White S, 2005, 'Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, pp. 266S - 266S, presented at 41st Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 13 May 2005 - 17 May 2005, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000230326601475&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander ML; Bishop J; Levi J; Zalcberg JR; Olver IN; Smith JV; Toner GC, 2005, 'A phase II trial of Paclitaxel in previously treated patients with metastatic breast cancer.', in Medical Journal of Australia, Australasian Med Publishing Company Ltd, Sydney, NSW, Australia, pp. 520 - 523, presented at Medical Journal of Australia

Thewes B; Meiser B; Duric V; Stockler M; Friedlander M, 2004, 'What survival benefits do pre-menopausal early breast cancer patients consider necessary to make endocrine therapy worthwhile?', in PSYCHO-ONCOLOGY, JOHN WILEY & SONS LTD, pp. S40 - S41, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000223957800084&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Aghmesheh M; Friedlander M; Russell PJ; Edwards L; Yang JL; Kconfab K; Nesland JM; Danielson H; Kaern J; Tucker KM, 2004, 'BRCA1 mutation site may associate with nuclear DNA content in BRCA1-associated ovarian carcinomas.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, LA, New Orleans, pp. 459S - 459S, presented at 40th Annual Meeting of the American-Society-of-Clinical-Oncology, LA, New Orleans, 05 June 2004 - 08 June 2004, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000223512401819&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Loi S; Milne RL; Friedlander ML; McCredie MRE; Giles GG; Hopper JL; Phillips KA, 2004, 'The impact of obesity on outcomes in a population-based cohort of women with early-onset breast cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, LA, New Orleans, pp. 845S - 845S, presented at 40th Annual Meeting of the American-Society-of-Clinical-Oncology, LA, New Orleans, 05 June 2004 - 08 June 2004, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000223512403351&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Thewes B; Meiser B; Rickard J; Friedlander M, 2003, 'The fertility and menopause related information needs of younger women with a diagnosis of breast cancer', in PSYCHO-ONCOLOGY, JOHN WILEY & SONS LTD, pp. S125 - S125, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000183225400153&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Aghmesheh M; Edwards L; Clarke CL; Russell PJ; Friedlander ML; Tucker K; Defazio A, 2002, 'Steroid hormone receptor expression in heriditary and sporadic ovarian cancers', in Proceedings of the American Association for Cancer Research, American Association Cancer Research, Philadelphia, PA, USA, pp. 6 - 6, presented at 93rd Annual Meeting of the AACR, San Francisco, California USA, 06 April 2002 - 10 April 2002

Apicella C; Andrews L; Tucker K; Bankier A; Friedlander M; Venter D; Hopper J, 1999, 'Australian Jewish women's experiences with a breast cancer gene testing program as part of the co-operative family registry for breast cancer studies (CFR-BCS).', in AMERICAN JOURNAL OF HUMAN GENETICS, UNIV CHICAGO PRESS, pp. A191 - A191, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000082879801051&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Links M; Friedlander M; Russell P, 1999, 'Enhancement of cisplatin cytotoxicity by caffeine does not correlate with abrogation of G2 arrest.', in BRITISH JOURNAL OF CANCER, CHURCHILL LIVINGSTONE, pp. 42 - 42, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000081955000151&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Bishop DT; Rapley E; Tucker K; Collins F; Donald J; Friedlander M; Peng HQ; Goss P; Hogg D; Easton DF; Teare D; Crockford G; Forman D; Leahy M; Bodmer JG; Moses J; Tonks S; Oliver RTD; Biggs P; Seal S; Barfoot R; Gill S; Patel S; Hamoudi R; Hunter R; Thomlinson I; Cooper C; Stratton M; Huddart R; Fosså SD; Heimdal K, 1998, 'Candidate regions for testicular cancer susceptibility genes: The International Testicular Cancer Linkage Consortium', in APMIS, pp. 64 - 72, http://dx.doi.org/10.1111/j.1699-0463.1998.tb01320.x

Friedlander M; DeGramont A; Millward MJ; Bell D; Bugat R; Harnett P; Moreno JA; Campbell L; Ripoche V; Kayitalire L, 1997, 'Activity of Gemcitabine in stage 3 or 4 ovarian cancer: Patients previously treated with cisplatin (CP)-containing regimens', in EUROPEAN JOURNAL OF CANCER, PERGAMON-ELSEVIER SCIENCE LTD, pp. 538 - 538, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1997XX83000533&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Rapley E; Tucker K; Collins F; Donald J; Friedlander M; Peng HQ; Goss P; Hogg D; Easton DF; Teare D; Bishop DT; Crockford G; Forman D; Leahy M; Bodmer JG; Moses J; Tonks S; Oliver RTD; Biggs P; Seal S; Barfoot R; Gill S; Patel S; Hamoudi R; Hunter R; Thomlinson I; Cooper C; Stratton M; Huddart R; Fossa SD; Heimdal K, 1997, 'Candidate regions for testicular cancer susceptibility genes', in APMIS, WILEY, DENMARK, COPENHAGEN UNIV HOSP, COPENHAGEN, pp. 64 - 70, presented at 4th Copenhagen Workshop on Carcinoma In Situ and Cancer of the Testis - Molecular and Endocrine Aspects, DENMARK, COPENHAGEN UNIV HOSP, COPENHAGEN, 18 May 1997 - 21 May 1997, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000072338300014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Zalcberg JR; Bishop JF; Millward MJ; Zimet A; Laird J; Barter C; Seward D; McKeage MJ; Friedlander ML; Toner G; Berille J; Blanc C, 1995, 'Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC)', in EUROPEAN JOURNAL OF CANCER, PERGAMON-ELSEVIER SCIENCE LTD, pp. 1084 - 1084, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1995TH91901079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

FRIEDLANDER ML; MUSGROVE L; RUSSELL P; TOPPLIA M; HEDLEY D; TAYLOR IW; TATTERSALL MHN, 1983, 'FLOW CYTOMETRIC ANALYSIS OF DNA CONTENT IN OVARIAN-CANCER', in CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, BLACKWELL SCIENCE, pp. 489 - 489, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1983RB75800115&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Proceedings (Editor of)

Tiller K; Meiser B; Tucker K; Andrews L; Gaff C; Kirk J; Phillips KA; Duding T; Friedlander ML, (eds.), 2003, '6th World Congress Psycho-Oncology', Banff Alberta Canada, presented at 6th World Congress Psycho-Oncology, Banff Alberta Canada, 23 April 2003 - 27 April 2003

Thewes B; Meiser B; Rickard J; Friedlander ML, (eds.), 2003, '6th World Congress Psycho-Oncology', Banff Alberta Canada, presented at 6th World Congress Psycho-Oncology, Banff Alberta Canada, 23 April 2003 - 27 April 2003

Conference Posters

Lemech CR; Friedlander M, 2009, 'Clear cell cancer of the ovary: from resistance to response', Canberra Australia, presented at MOGA Annual Scientific Meeting, Canberra Australia, 12 August 2009 - 14 August 2009, http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2009.01218.x/pdf

Conference Presentations

Hayes S; Friedlander M; Obermair A; Mileshkin L; Janda M; Gordon L; Barnes E; Beesley V; Eakin E; Sommeijer D; Martyn J; Stockler M; Gebski VAL; Naumann F; Schmitz K; Webb P, 2014, 'EXERCISE DURING CHEMOTHERAPY FOR OVARIAN CANCER (ECHO): STUDY DESIGN FEATURES AND OUTCOMES OF A CANCER AUSTRALIA AND CANCER COUNCIL AUSTRALIA FUNDED RANDOMISED, CONTROLLED TRIAL', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500161&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts

Symons R; Heath F; Duggan J; Bui KT; Byun L; Friedlander M; Lee YC, 2024, 'Rates of paclitaxel hypersensitivity reactions using a modified Markman’s infusion protocol as primary prophylaxis', in Supportive Care in Cancer, Vol. 32, http://dx.doi.org/10.1007/s00520-024-08460-z

Pitiyarachchi O; Lee YC; Ramus SJ; defazio A; Friedlander M, 2022, 'Rates of somatic variants in homologous recombination DNA repair deficiency genes in older patients with high-grade serous ovarian carcinoma', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 30 - 30, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000879941200024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

DiSilvestro P; Banerjee S; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander ML; Lisyanskaya AS; Floquet A; Leary A; Sonke GS; Gourley C; Oza AM; Martin AJG; Aghajanian C; Bradley WH; Mathews C; McNamara J; Lowe E; Moore KN, 2022, 'Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S779 - S779, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, http://dx.doi.org/10.1016/j.annonc.2022.07.645

Deva S; Millward M; Friedlander M; Gan HK; Hovarth LG; Lee J-S; Hill A; Sandhu S; Liang L; Shi J; Zhang Y; Shi Y; Ma X; Wu X; Shen Z; Desai J, 2022, 'Abstract LB511: The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab', in Cancer Research, American Association for Cancer Research (AACR), Vol. 82, pp. LB511 - LB511, http://dx.doi.org/10.1158/1538-7445.am2022-lb511

Tan DSP; Choi CH; Ngoi N; Sun H; Heong V; Ow SGW; Chay WY; Kim HS; Lim YW; Goss G; Goh JC; Luo V; Tai BC; Lim D; Kaliaperumal N; Au VB; Connolly J; Kim J-W; Friedlander M; Kim K, 2022, 'A multicenter phase II randomized trial of durvalumab (D) versus physician's choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301622&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Tan DSP; Choi CH; Ngoi N; Sun H; Heong V; Ow SGW; Chay WY; Kim HS; Lim YW; Goss G; Goh JC; Luo V; Tai BC; Lim D; Kaliaperumal N; AU VB; Connolly J; Kim J-W; Friedlander M; Kim K, 2022, 'A multicenter phase II randomized trial of durvalumab (D) versus physician’s choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5565 - 5565, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5565

Woodford R; Zhou D; Kok P-S; Lord S; Friedlander M; Marschner I; Simes J; Lee CK, 2022, 'Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 6518 - 6518, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.6518

Woodford R; Zhou D; Kok P-S; Lord S; Friedlander M; Marschner I; Simes J; Lee CK, 2022, 'Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301818&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mizrahi D; Goldstein D; Trinh T; Li T; Timmins HC; Harrison M; Marx GM; Hovey EJ; Lewis CR; Friedlander M; Park SB, 2022, 'Clinical Predictors And Levels Of Physical Activity Among Cancer Survivors Treated With Neurotoxic Chemotherapy', in Medicine & Science in Sports & Exercise, LIPPINCOTT WILLIAMS & WILKINS, San Diego, California, Vol. 54, pp. 322 - 322, presented at ACSM 2022 Annual Meeting & World Congresses, San Diego, California, 31 May 2022 - 04 June 2022, http://dx.doi.org/10.1249/01.mss.0000879060.88938.0b

Meagher NS; Hamilton PT; Anglesio MS; Harris HR; Konecny GE; Schildkraut JM; Talhouk A; Friedlander ML; Pearce CL; Pike MC; Kobel M; Doherty JA; Goode EL; Nelson BH; DeFazio A; Ramus SJ, 2022, 'Multi-modal immune profiling of mucinous ovarian carcinoma: analysis from the Ovarian Tumor Tissue Analysis/Multidisciplinary Ovarian Cancer Outcomes Group consortia', in JOURNAL OF IMMUNOLOGY, AMER ASSOC IMMUNOLOGISTS, Vol. 208, http://dx.doi.org/10.4049/jimmunol.208.Supp.179.04

Trillsch F; Mahner S; Ataseven B; Asher R; Aryal N; Dubot C; Clamp A; Penson RT; Oza A; Amit A; Huzarski T; Casado A; Scambia G; Friedlander M; Colombo N; Fujiwara K; Sonke GS; Denys H; Lowe ES; Lee CK; Pujade-Lauraine E, 2022, 'Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study', in Gynecologic Oncology, Vol. 165, pp. 40 - 48, http://dx.doi.org/10.1016/j.ygyno.2022.01.024

Simon S; Francis K; Dalrymple J; Gebski V; Lord S; Friedlander M; Lee CK, 2021, 'Adverse events experienced by patients in the placebo arm of maintenance therapy trials in advanced ovarian cancer', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S745 - S745, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1195

Ngoi NYL; Tan TZ; Kuay KT; Tan ACY; Lee JY; Pang MY; Tham KW; Chan J; Wong WL; Chay WY; Anne D; Friedlander M; Varma S; Meniawy T; Au-Yeung G; Scott C; Mileshkin L; Bowtell D; Huang RY-J; Tan DSP, 2021, 'Phase II study of IV vinorelbine in relapsed platinum resistant or refractory C5 high grade serous primary peritoneal, fallopian tube or ovarian cancer (VIP)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S736 - S736, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1179

Mapagu C; Srirangan S; Pattnaik S; Nevins N; Provan P; Bouantoun N; Kirk J; Chiew Y-E; Dobrovic A; Musafer A; Zhang F; Balleine R; Beale P; Bowtell D; Brand A; Friedlander M; Harnett P; Marsh D; Goli S; deFazio A, 2021, 'Assessment of HR deficiency in ovarian cancer to increase PARP inhibitor targets beyond BRCA1/2', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 54 - 55, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000103&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Pavanello M; Chiew Y-E; Mapagu C; Srirangan S; Nevins N; Bouantoun N; Pattnaik S; Gao B; Kennedy CJ; Boros J; Provan P; Friedlander M; Samimi G; Brand A; Marsh DJ; Beale P; Anderson L; Bowtell DDL; Balleine RL; Harnett PR; DeFazio A, 2021, 'Cyclin E1 (CCNE1) gene amplification assessment in prospectively recruited ovarian cancer patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 67 - 68, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000129&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Gersekowski K; Jordan S; Delahunty R; Alsop K; Goode EL; Bowtell D; DeFazio A; Friedlander M; Obermair A; Grant P; Webb P, 2021, 'Impact of BRCA mutation status and lifestyle factors on survival among women with ovarian cancer', in INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, OXFORD UNIV PRESS, Vol. 50, pp. 79 - 79, http://dx.doi.org/10.1093/ije/dyab168.217

Meagher N; Koebel M; Anderson L; Tan A; Bolithon A; Anglesio M; Cohen P; Crowe P; Doherty J; Fasching P; Harris H; Hogdall E; Huntsman D; James P; Karlan B; Kelemen L; Kommoss S; Konecny G; Gorringe K; Modugno F; Park S; Pharoah P; Staebler A; Sundfeldt K; Thorne H; Wu A; DeFazio A; Friedlander M; Ramus S, 2021, 'Pattern of invasion in stage I mucinous ovarian cancer is prognostic within 2-years of diagnosis', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 47 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000088&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Bradley W; Moore K; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke G; Gourley C; Banerjee S; Oza A; Gonzalez-Martin A; Aghajanian C; Cain T; Lowe E; DiSilvestro P, 2021, 'Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, Vol. 162, pp. S25 - S26, http://dx.doi.org/10.1016/S0090-8258(21)00694-6

Smith D; Robledo K; Yip S; Cummins M; Kok P-S; Lee YC; Friedlander M; Baron-Hay SE; Shannon CM; Coward J; Beale PJ; Goss G; Meniawy T; Lombard JM; Spurdle AB; Andrews J; Stockler MR; Mileshkin LR; Antill YC, 2021, 'Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 04 June 2021 - 08 June 2021, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.5584

Woodford R; Zhou D; Kok P-S; Lord S; Marschner I; Friedlander M; Lee CK, 2021, 'The validity of progression-free survival (PFS) 2 as a surrogate endpoint for overall survival (OS) in randomized controlled trials (RCTs) of advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.1516

Feiglin T; Armstrong G; Sinha R; Robertson G; Friedlander M; Wan K, 2021, 'Two Cases of Intraplacental Choriocarcinoma Causing Severe Fetal Anaemia at Term', in AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, WILEY, Vol. 61, pp. 7 - 7, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000651190000006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page